PPII Coenzyme A Inc (CE)

Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary, Coenzyme-A Technologies, Inc., is pleased to announce it is continuing the distribution negotiations with ERC Saglik Urunleri, a Mediterranean Company, and also Global Pharmaceuticals, a Middle Eastern and North African Company. Both of these companies are leading international wholesale pharmaceutical distributors for medical-optical devices, pharmaceutical equipment and nutraceutical products and have large customer bases in the Mediterranean region, North Africa and the Middle East territories. ERC Saglik Urunleri is currently serving many of the over 1,100 hospitals, 18,000 independent pharmacies and approximately 22,000 independent medical practices in their respective territories.

Verbal negotiations have indicated that an Opening Order by ERC Saglik Urunleri alone is estimated to be at 500,000 individual units of the "Pure Coenzyme-A" nutraceutical product development. This translates to approx. over $15,000,000.00 in sales alone from this pending business transaction. These two pending agreements could possibly bring the company's annual earnings from approx. $500,000.00 in 2009 to well over the $30,000,000.00 million mark during the course of 2010.

ABOUT COENZYME-A TECHNOLOGIES, INC. - Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the deleterious effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.

FORWARD-LOOKING STATEMENTS The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contact Information: Pro-Pointer, Inc. 458 Coral Sea St. Henderson, Nv. 89074 Ph-702-458-4111 Cell-702-591-7440